Skip to main content
. 2020 Jul 16;13:1756284820938960. doi: 10.1177/1756284820938960

Figure 3.

Figure 3.

Clinical remission at weeks 4 and 26, intent-to-treat population. Patients with response (decrease in CDAI ⩾70 from baseline; NRI) at week 8 were compared at week 26 with a prespecified, clinically relevant threshold of 30%.

ADA, adalimumab; CDAI, Crohn’s disease activity index; NRI, non-responder imputation; PBO, placebo.